Investigating how chromosomal instability and loss of chromosome 17p affect cancer cell sensitivity to NDE1 depletion
Official title: Chromosomal Instability and 17p Loss Sensitize Cancer Cells to NDE1 Depletion
Funded at Duke University · NIH-11080752 · Data updated 2026-11-12
This study is looking at how certain changes in cancer cells, specifically in advanced metastatic cancers, can help us find new ways to treat them by targeting a protein called NDE1, which might make these cancer cells grow slower.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | May 1, 2024 |
| Project end | July 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $48,854 |
| NIH project number | 5F31CA287604-02 |
| Project ID | NIH-11080752 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with advanced metastatic cancers that show chromosomal instability and loss of chromosome 17p.
✕Less likely to help
Patients whose cancers do not exhibit chromosomal instability or loss of chromosome 17p may not benefit from this research.
What this research studies
This research explores the relationship between chromosomal instability (CIN) and the loss of the short arm of chromosome 17 (17p) in advanced metastatic cancers. By using a whole-genome CRISPR/Cas9 screening approach, the study aims to identify genetic dependencies that arise from these alterations. The focus is on how inhibiting a specific protein, NDE1, can selectively target and inhibit the growth of cancer cells that exhibit these genetic features. Patients may benefit from insights that could lead to new targeted therapies for their cancers.
Why it matters
Potential benefit: If successful, this research could lead to new targeted treatments for cancers characterized by chromosomal instability and 17p loss.
How similar studies have gone: Previous research has shown promising results in targeting chromosomal instability in cancer, suggesting that this approach may yield significant insights.
Where this research is happening
-
Duke University
Durham, United States Active
Researchers
- Principal investigator: Bridgwater, Caroline Marie — Duke University
- Study coordinator: Bridgwater, Caroline Marie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.